Therapeutic Approaches for Clostridium difficile Infections

Jane W. Marsh1, Scott R. Curry1

1 Epidemiology Research Unit, University of Pittsburgh, Pittsburgh, Pennsylvania
Publication Name:  Current Protocols in Microbiology
Unit Number:  Unit 9A.3
DOI:  10.1002/9780471729259.mc09a03s30
Online Posting Date:  October, 2013
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library

Abstract

Metronidazole and vancomycin remain the front‐line therapies for most Clostridium difficile infections (CDI). However, recurrent CDI occurs in ∼25% of patients, causing significant morbidity and mortality and healthcare costs. For this population, traditional antibiotic therapies fail and new treatment options are greatly needed. The US Food and Drug Administration recently approved fidaxomicin for CDI treatment. This narrow‐spectrum antibiotic preserves the normal gut microbiota and shows promise as a treatment for severe and recurrent CDI. Monoclonal antibodies and vaccines directed against toxin are currently in clinical trials and represent alternative, non‐antibiotic therapies. Less traditional therapeutic interventions include bacteriotherapy with non‐toxigenic C. difficile and fecal transplant. This commentary will provide an overview of current and forthcoming CDI therapies. Curr. Protoc. Microbiol. 30:9A.3.1‐9A.3.9. © 2013 by John Wiley & Sons, Inc.

Keywords: colitis; antibiotics; diarrhea; vaccine

     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Table of Contents

  • Introduction
  • Epidemiology
  • Disruption of Colonization Resistance
  • CDI Risk Factors
  • Host Immunity
  • Antimicrobial Therapies
  • Antimicrobial Treatment Guidelines
  • Alternative Therapeutic Approaches
  • Literature Cited
  • Figures
  • Tables
     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Materials

GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Figures

Videos

Literature Cited

Literature Cited
  Babakhani, F., Gomez, A., Robert, N., and Sears, P. 2011. Postantibiotic effect of fidaxomicin and its major metabolite, OP‐1118, against Clostridium difficile. Antimicrob. Agents Chemother. 55:4427‐4429.
  Babakhani, F., Bouillaut, L., Gomez, A., Sears, P., Nguyen, L., and Sonenshein, A.L. 2012a. Fidaxomicin inhibits spore production in Clostridium difficile. Clin. Infect. Dis. 55:S162‐S169.
  Babakhani, F., Bouillaut, L., Sears, P., Sims, C., Gomez, A., and Sonenshein, A.L. 2012b. Fidaxomicin inhibits toxin production in Clostridium difficile. J. Antimicrob. Chemother. 68:515‐522.
  Babcock, G.J., Broering, T.J., Hernandez, H.J., Mandell, R.B., Donahue, K., Boatright, N., Stack, A.M., Lowy, I., Graziano, R., Molrine, D., Ambrosino, D.M., and Thomas, W.D. Jr. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile‐induced mortality in hamsters. Infect. Immun. 74:6339‐6347.
  Belmares, J., Gerding, D.N., Parada, J.P., Miskevics, S., Weaver, F., and Johnson, S. 2007. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J. Infect. 55:495‐501.
  Borriello, S.P. and Barclay, F.E. 1985. Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non‐pathogenic strains. J. Med. Microbiol. 19:339‐350.
  CDC. 2005. Severe Clostridium difficile‐associated disease in populations previously at low risk—four states, 2005. MMWR Morb. Mortal. Wkly. Rep. 54:1201‐1205.
  CDC. 2008. Surveillance for community‐associated Clostridium difficile—Connecticut, 2006. MMWR Morb. Mortal. Wkly. Rep. 57:340‐343.
  Chang, J.Y., Antonopoulos, D.A., Kalra, A., Tonelli, A., Khalife, W.T., Schmidt, T.M., and Young, V.B. 2008. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile‐associated diarrhea. J. Infect. Dis. 197:435‐438.
  Clabots, C.R., Johnson, S., Olson, M.M., Peterson, L.R., and Gerding, D.N. 1992. Acquisition of Clostridium difficile by hospitalized patients: Evidence for colonized new admissions as a source of infection. J. Infect. Dis. 166:561‐567.
  Cornely, O.A., Crook, D.W., Esposito, R., Poirier, A., Somero, M.S., Weiss, K., Sears, P., Gorbach, S., and OPT‐80‐004 Clinical Study Group. 2012a. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double‐blind, non‐inferiority, randomised controlled trial. Lancet Infect. Dis. 12:281‐289.
  Cornely, O.A., Miller, M.A., Louie, T.J., Crook, D.W., and Gorbach, S.L. 2012b. Treatment of first recurrence of Clostridium difficile infection: Fidaxomicin versus vancomycin. Clin. Infect. Dis. 55:S154‐S161.
  Credito, K.L. and Appelbaum, P.C. 2004. Activity of OPT‐80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob. Agents Chemother. 48:4430‐4434.
  Crook, D.W., Walker, A.S., Kean, Y., Weiss, K., Cornely, O.A., Miller, M.A., Esposito, R., Louie, T.J., Stoesser, N.E., Young, B.C., Angus, B.J., Gorbach, S.L., Peto, T.E., and Study 003/004 Teams. 2012. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta‐analysis of pivotal randomized controlled trials. Clin. Infect. Dis. 55:S93‐S103.
  Curry, S.R., Marsh, J.W., Shutt, K.A., Muto, C.A., O'Leary, M.M., Saul, M.I., Pasculle, A.W., and Harrison, L.H. 2009. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin. Infect. Dis. 48:425‐429.
  Davies, A.H., Roberts, A.K., Shone, C.C., and Acharya, K.R. 2011. Super toxins from a super bug: Structure and function of Clostridium difficile toxins. Biochem. J. 436:517‐526.
  Debast, S.B., van Leengoed, L.A., Goorhuis, A., Harmanus, C., Kuijper, E.J., and Bergwerff, A.A. 2009. Clostridium difficile PCR ribotype 078 toxinotype V found in diarrhoeal pigs identical to isolates from affected humans. Environ. Microbiol. 11:505‐511.
  Dumyati, G., Stevens, V., Hannett, G.E., Thompson, A.D., Long, C., Maccannell, D., and Limbago, B. 2012. Community‐associated Clostridium difficile infections, Monroe County, New York, USA. Emerg. Infect. Dis. 18:392‐400.
  Edwards, D.I., Thompson, E.J., Tomusange, J., and Shanson, D. 1979. Inactivation of metronidazole by aerobic organisms. J. Antimicrob. Chemother. 5:315‐316.
  Figueroa, I., Johnson, S., Sambol, S.P., Goldstein, E.J., Citron, D.M., and Gerding, D.N. 2012. Relapse versus reinfection: Recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin. Infect. Dis. 55:S104‐S109.
  Freter, R. 1955. The fatal enteric cholera infection in the guinea pig, achieved by inhibition of normal enteric flora. J. Infect. Dis. 97:57‐65.
  Garey, K.W., Jiang, Z.D., Bellard, A., and Dupont, H.L. 2009. Rifaximin in treatment of recurrent Clostridium difficile‐associated diarrhea: An uncontrolled pilot study. J. Clin. Gastroenterol. 43:91‐93.
  Garey, K.W., Ghantoji, S.S., Shah, D.N., Habib, M., Arora, V., Jiang, Z.D., and DuPont, H.L. 2011. A randomized, double‐blind, placebo‐controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J. Antimicrob. Chemother. 66:2850‐2855.
  Giannasca, P.J., Zhang, Z.X., Lei, W.D., Boden, J.A., Giel, M.A., Monath, T.P., and Thomas, W.D. Jr. 1999. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect. Immun. 67:527‐538.
  Gough, E., Shaikh, H., and Manges, A.R. 2011. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis. 53:994‐1002.
  Greenberg, R.N., Marbury, T.C., Foglia, G., and Warny, M. 2012. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 30:2245‐2249.
  He, M., Miyajima, F., Roberts, P., Ellison, L., Pickard, D.J., Martin, M.J., Connor, T.R., Harris, S.R., Fairley, D., Bamford, K.B., D'Arc, S., Brazier, J., Brown, D., Coia, J.E., Douce, G., Gerding, D., Kim, H.J., Koh, T.H., Kato, H., Senoh, M., Louie, T., Michell, S., Butt, E., Peacock, S.J., Brown, N.M., Riley, T., Songer, G., Wilcox, M., Pirmohamed, M., Kuijper, E., Hawkey, P., Wren, B.W., Dougan, G., Parkhill, J., and Lawley, T.D. 2012. Emergence and global spread of epidemic healthcare‐associated Clostridium difficile. Nat. Genet. 45:109‐113.
  Hirshon, J.M., Thompson, A.D., Limbago, B., McDonald, L.C., Bonkosky, M., Heimer, R., Meek, J., Mai, V., and Braden, C. 2011. Clostridium difficile infection in outpatients, Maryland and Connecticut, USA, 2002‐2007. Emerg. Infect. Dis. 17:1946‐1949.
  Jhung, M.A., Thompson, A.D., Killgore, G.E., Zukowski, W.E., Songer, G., Warny, M., Johnson, S., Gerding, D.N., McDonald, L.C., and Limbago, B.M. 2008. Toxinotype V Clostridium difficile in humans and food animals. Emerg. Infect. Dis. 14:1039‐1045.
  Jiang, Z.D., Ke, S., Palazzini, E., Riopel, L., and Dupont, H. 2000. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob. Agents Chemother. 44:2205‐2206.
  Johnson, S., Schriever, C., Galang, M., Kelly, C.P., and Gerding, D.N. 2007. Interruption of recurrent Clostridium difficile‐associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin. Infect. Dis. 44:846‐848.
  Johnson, S., Schriever, C., Patel, U., Patel, T., Hecht, D.W., and Gerding, D.N. 2009. Rifaximin Redux: Treatment of recurrent Clostridium difficile infections with rifaximin immediately post‐vancomycin treatment. Anaerobe 15:290‐291.
  Khoruts, A., Dicksved, J., Jansson, J.K., and Sadowsky, M.J. 2010. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile‐associated diarrhea. J. Clin. Gastroenterol. 44:354‐360.
  Kim, P.H., Iaconis, J.P., and Rolfe, R.D. 1987. Immunization of adult hamsters against Clostridium difficile‐associated ileocecitis and transfer of protection to infant hamsters. Infect. Immun. 55:2984‐2992.
  Kyne, L., Warny, M., Qamar, A., and Kelly, C.P. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342:390‐397.
  Kyne, L., Warny, M., Qamar, A., and Kelly, C.P. 2001. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357:189‐193.
  Larson, K.C., Belliveau, P.P., and Spooner, L.M. 2011. Tigecycline for the treatment of severe Clostridium difficile infection. Ann. Pharmacother.45:1005‐1010.
  Louie, T.J., Miller, M.A., Mullane, K.M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., Shue, Y.K., and OPT‐80‐003 Clinical Study Group. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364:422‐431.
  Lowy, I., Molrine, D.C., Leav, B.A., Blair, B.M., Baxter, R., Gerding, D.N., Nichol, G., Thomas, W.D. Jr., Leney, M., Sloan, S., Hay, C.A., and Ambrosino, D.M. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362:197‐205.
  Manges, A.R., Labbe, A., Loo, V.G., Atherton, J.K., Behr, M.A., Masson, L., Tellis, P.A., and Brousseau, R. 2010. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile‐associated disease. J. Infect. Dis. 202:1877‐1884.
  Marsh, J.W., Arora, R., Schlackman, J.L., Shutt, K.A., Curry, S.R., and Harrison, L.H. 2012. Association of relapse of Clostridium difficile disease with BI/NAP1/027. J. Clin. Microbiol. 50:4078‐4082.
  McFarland, L.V., Mulligan, M.E., Kwok, R.Y., and Stamm, W.E. 1989. Nosocomial acquisition of Clostridium difficile infection. N. Engl. J. Med. 320:204‐210.
  Musher, D.M., Aslam, S., Logan, N., Nallacheru, S., Bhaila, I., Borchert, F., and Hamill, R.J. 2005. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 40:1586‐1590.
  Muto, C.A., Blank, M.K., Marsh, J.W., Vergis, E.N., O'Leary, M.M., Shutt, K.A., Pasculle, A.W., Pokrywka, M., Garcia, J.G., Posey, K., Roberts, T.L., Potoski, B.A., Blank, G.E., Simmons, R.L., Veldkamp, P., Harrison, L.H., and Paterson, D.L. 2007. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive “bundle” approach. Clin. Infect. Dis. 45:1266‐1273.
  Nair, S., Yadav, D., Corpuz, M., and Pitchumoni, C.S. 1998. Clostridium difficile colitis: Factors influencing treatment failure and relapse—a prospective evaluation. Am. J. Gastroenterol. 93:1873‐1876.
  Noren, T., Akerlund, T., Back, E., Sjoberg, L., Persson, I., Alriksson, I., and Burman, L.G. 2004. Molecular epidemiology of hospital‐associated and community‐acquired Clostridium difficile infection in a Swedish county. J. Clin. Microbiol. 42:3635‐3643.
  O'Connor, J.R., Galang, M.A., Sambol, S.P., Hecht, D.W., Vedantam, G., Gerding, D.N., and Johnson, S. 2008. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob. Agents Chemother. 52:2813‐2817.
  Olson, M.M., Shanholtzer, C.J., Lee, J.T. Jr., and Gerding, D.N. 1994. Ten years of prospective Clostridium difficile‐associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982‐1991. Infect. Control Hosp. Epidemiol. 15:371‐381.
  Peláez, T., Cercenado, E., Alcalá, L., Marín, M., Martín‐López, A., Martínez‐Alarcón, J., Catalán, P., Sánchez‐Somolinos, M., and Bouza, E. 2008. Metronidazole resistance in Clostridium difficile is heterogeneous. J. Clin. Microbiol. 46:3028‐3032.
  Pepin, J., Valiquette, L., and Cossette, B. 2005. Mortality attributable to nosocomial Clostridium difficile‐associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173:1037‐1042.
  Permpoonpattana, P., Hong, H.A., Phetcharaburanin, J., Huang, J.M., Cook, J., Fairweather, N.F., and Cutting, S.M. 2011. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect. Immun. 79:2295‐2302.
  Sambol, S.P., Merrigan, M.M., Tang, J.K., Johnson, S., and Gerding, D.N. 2002. Colonization for the prevention of Clostridium difficile disease in hamsters. J. Infect. Dis. 186:1781‐1789.
  Smith, D.G. and Robinson, H.J. 1945. The influence of streptomycin and streptothricin on the intestinal flora of mice. J. Bacteriol. 50:613‐621.
  Sougioultzis, S., Kyne, L., Drudy, D., Keates, S., Maroo, S., Pothoulakis, C., Giannasca, P.J., Lee, C.K., Warny, M., Monath, T.P., and Kelly, C.P. 2005. Clostridium difficile toxoid vaccine in recurrent C. difficile‐associated diarrhea. Gastroenterology 128:764‐770.
  Teasley, D.G., Gerding, D.N., Olson, M.M., Peterson, L.R., Gebhard, R.L., Schwartz, M.J., and Lee, J.T. Jr. 1983. Prospective randomised trial of metronidazole versus vancomycin for Clostridium‐difficile‐associated diarrhoea and colitis. Lancet 2:1043‐1046.
  Tian, J.H., Fuhrmann, S.R., Kluepfel‐Stahl, S., Carman, R.J., Ellingsworth, L., and Flyer, D.C. 2012. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine 30:4249‐4258.
  Vardakas, K.Z., Polyzos, K.A., Patouni, K., Rafailidis, P.I., Samonis, G., and Falagas, M.E. 2012. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: A systematic review of the evidence. Int. J. Antimicrob. Agents 40:1‐8.
  Villano, S.A., Seiberling, M., Tatarowicz, W., Monnot‐Chase, E., and Gerding, D.N. 2012. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob. Agents Chemother. 56:5224‐5229.
  Voth, D.E. and Ballard, J.D. 2005. Clostridium difficile toxins: Mechanism of action and role in disease. Clin. Microbiol. Rev. 18:247‐263.
  Warny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., Frost, E., and McDonald, L.C. 2005. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079‐1084.
  Wenisch, C., Parschalk, B., Hasenhundl, M., Hirschl, A.M., and Graninger, W. 1996. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile‐associated diarrhea. Clin. Infect. Dis. 22:813‐818.
  Wilson, K.H. and Sheagren, J.N. 1983. Antagonism of toxigenic Clostridium difficile by nontoxigenic C. difficile. J. Infect. Dis. 147:733‐736.
  Zar, F.A., Bakkanagari, S.R., Moorthi, K.M., and Davis, M.B. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile‐associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45:302‐307.
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library